Transgene (TNG: FP), a French biotechnology company with the ambitious goal of taking oncolytic viruses to the market is facing a significant hurdle. A clinical trial reviewed by an independent group deemed their trial meant to treat patients with liver cancer (HPC) useless. A blow to Transgene’s hope to break a market that is worth $44 Billion by 2023.
Transgene’s scientists engineered an oncolytic vaccinia virus to be armed with GM-CSF, a gene that promotes an immune response and anti-tumor effects. A brilliant idea, the mechanism behind GM-CSF is to kick start the immune system. A promoter of white blood cells, granulocytes, macrophages and platelets, cells that are necessary to help fight off cancer and solid tumors. Solid tumors remain a mystery for many scientists and researchers as they continue their pursuit of discovering new ways to break-in. A need that is still unmet by big pharma and biotech; to this date, patients with solid tumors need radiation or surgery. These treatments become more complicated when a patient’s tumor is present near crucial organs.
The news of Transgene’s failure in phase III shook many investors who saw Transgene as the next billion-dollar biotech company. As soon as the press release came for PEXA-VAC and its phase III flop, investors were selling Transgene to stop any further losses. The stock took a loss of more than 20 percent, tanking it from 2.34 to 1.85 a share, making many investors cautious in investing in biotech companies with similar ambitions.
Although Transgene did not disclose why they decided to stop PEXA-VEC, we can assume that the independent group didn’t find any benefits to patients. A surprise for many investors, who have heard pitches from biotechnology start-ups and pharmaceutical giants investing in oncolytic virus research. Hopefully, Transgene’s failure with HPC patients isn’t foreshadowing the future of where the industry and similar programs will go.
Do you like what you’re reading? Visit Biotechbrothers.com and subscribe to our newsletter!